Gabapentin
Product Images NDC 45865-122

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45865-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets 600 mg 60's (Pdp 122)

Label for Gabapentin Tablets 600 mg by Medsource Pharmaceuticals. The label states the product as generic for Neurontin, white scored film-coated tablets with NDC 45865-0122-60. It includes a warning about possible dizziness or drowsiness and instructions to avoid alcohol. The label indicates a fill quantity of 150 tablets and provides space for dosage directions and expiration date.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr), involving age, weight, serum creatinine, and a factor of 0.85 for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid group. The diagram highlights the molecular arrangement of the active ingredient Gabapentin.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing the mean pain score over 8 weeks between placebo and Gabapentin at 3600 mg/day. The x-axis shows weeks including baseline; the y-axis represents the mean pain score from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period with the Gabapentin group showing a decrease in pain score compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period, comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a greater reduction in mean pain score compared to placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. The chart shows percentages of responders with higher proportions in GBP groups (29% and 32%-34%) versus placebo (12%-14%), with statistical significance indicated.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing the percentage difference versus daily dose in mg for gabapentin across three studies labeled a, b, and c. The x-axis shows daily dose ranging from 600 to 1800 mg, while the y-axis shows difference percentage from 2% to 22%. Each study's values are represented by different colored markers: black squares for study a, gray squares for study b, and white squares for study c, plotted at various dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.